	Stent-less strategy	Stent strategy	P
Number	30	30	
Age	67.30±11.12	70.63±8.97	0.206
Gender male/ female	20 / 10	24 / 6	0.243
Hypertension (n; %)	23 (76.7)	27 (93.3)	0.166
Dyslipidemia (n; %)	24 (80.0)	23 (76.7)	0.754
Triglyceride (mg/dl)	131.03±50.45	124.13±73.22	0.672
HDL-cholesterol (mg/dl)	48.13±13.01	47.67±16.59	0.904
LDL-cholesterol (mg/dl)	97.60±32.01	86.63±22.88	0.133
Diabetes mellitus (n; %)	12 (40.0)	13 (43.3)	0.793
HbA1c (%)	6.19±0.93	6.38±1.03	0.441
CKD	2 (6.7)	4 (13.3)	0.440
eGFR (ml/min/1.73m^2)	68.53±21.94	68.14±20.78	0.944
Family history (n; %)	4 (13.3)	3 (10.0)	0.688
Smoking (n; %)	17 (56.7)	19 (63.3)	0.598

Values are mean ±SD

HDL: high-density lipoprotein LDL: low-density lipoprotein HbA1c: hemoglobin A1c
CKD: chronic kidney disease eGFR: estimated glomerular filtration rate

Table 1 Baseline characteristics (coronary risk factors)

	Stent-less strategy	Stent strategy	P
Number	30	30	
Medical treatment			
ACEI&ARB (n; %)	25 (83.3)	28 (93.3)	0.228
CC-blocker (n; %)	16 (53.3)	17 (56.7)	0.795
Beta-blocker (n; %)	18 (60.0)	19 (63.3)	0.791
Statin (n; %)	28 (93.3)	28 (93.3)	>0.999
SU	1 (3.3)	2 (6.7)	0.554
α-Glucosidase (n; %)	3 (10.0)	6 (20.0)	0.278
Pioglitazone (n; %)	0 (0.0)	2 (6.7)	0.150
DPP-4 inhibitor (n; %)	6 (20.0)	9 (30.0)	0.371
Biguanide (n; %)	4 (13.3)	2 (6.7)	0.389
Insulin (n; %)	0 (0.0)	2 (6.7)	0.150

ACE inhibitor: angiotensin converting enzyme inhibitor ARB: angiotensin receptor blocker
SU: sulfonylurea DPP-4 inhibitor: Dipeptidyl peptidase-4 inhibitor

Table 2 baseline characteristics (medical treatment)

	DCB	DES	P value
Number	27	33	
Lesion location			0.699
LAD (n; %)	12	17	
LCx (n; %)	4	6	
RCA (n; %)	11	10	
AHA lesion classification (B2/C) (n; %)	12 (44.4)	20 (60.6)	0.212
Device size (mm)	3.08±0.48	2.99±0.37	0.401
Device length (mm)	20.93±5.12	23.00±8.02	0.250

Values are n (%) or mean ±SD

DCB: drug-coated balloon   DES: drug-eluting stent LAD: left antero-descending artery LCX: left circumflex artery RCA: right coronary artery AHA: American Heart Association

Table 3 lesion characteristics

	DCB	DES	P
Number	27	33	
TLR (n; %)	0 (0.0)	2 (6.1)	0.193
QCA analysis			
Before PCI			
Lesion length (mm)	16.13±5.25	18.14±7.41	0.241
RD (mm)	2.88±0.57	2.72±0.64	0.327
MLD (mm)	0.73±0.38	0.61±0.31	0.149
% DS (%)	74.78±10.23	76.86±11.52	0.466
Immediately after PCI			
MLD (mm)	2.36±0.46	2.64±0.37	0.011
% DS (%)	11.64±5.49	10.72±4.86	0.495
Acute gain (mm)	1.63±0.41	2.08±0.37	< 0.0001
Follow up data			
MLD (mm)	2.12±0.42	2.32±0.52	0.121
% DS (%)	14.37±8.29	15.97±15.87	0.639
Late lumen loss (mm)	0.25±0.25	0.37±0.40	0.185

DCB: drug-coated balloon   DES: drug-eluting stent   Values are mean ±SD

TLR: target lesion revascularization QCA: quantitative coronary analysis

PCI: percutaneous coronary intervention RD: reference diameter MLD: minimum lumen diameter

Table 4 TLR rate and QCA analysis